Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Network Meta-analysis and Cost-effectiveness Analysis

IMPORTANCE: Nivolumab and pembrolizumab are approved for treating platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Physicians and patients are uncertain which drug is preferable, rendering a cost-effectiveness comparison between them necessary. OBJECTIVE...

Descripción completa

Detalles Bibliográficos
Autores principales: Pei, Rui, Shi, Yin, Lv, Shuhe, Dai, Tingting, Zhang, Fengyu, Liu, Shao, Wu, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103222/
https://www.ncbi.nlm.nih.gov/pubmed/33956130
http://dx.doi.org/10.1001/jamanetworkopen.2021.8065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103222/
https://www.ncbi.nlm.nih.gov/pubmed/33956130
http://dx.doi.org/10.1001/jamanetworkopen.2021.8065

Ejemplares similares